Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:2015:456895.
doi: 10.1155/2015/456895. Epub 2015 Jan 21.

Five-aminosalicylic Acid: an update for the reappraisal of an old drug

Cristiana Perrotta  1 , Paolo Pellegrino  1 , Eliana Moroni  2 , Clara De Palma  1 , Davide Cervia  3 , Piergiorgio Danelli  2 , Emilio Clementi  4
Affiliations
Review

Five-aminosalicylic Acid: an update for the reappraisal of an old drug

Cristiana Perrotta et al. Gastroenterol Res Pract. 2015.

Abstract

Inflammatory bowel disease (IBD) comprises several conditions with chronic or recurring immune response and inflammation of the gastrointestinal apparatus, of which ulcerative colitis and Crohn's disease are the commonest forms. This disease has a significant prevalence and it is of an unknown aethiology. Five-aminosalicylic acid (5-ASA) and its derivatives are among the oldest drugs approved for the treatment of the IBD. In this review we reapprise aspects of 5-ASA mechanism of action, safety, and efficacy that in our opinion make it a valuable drug that can be fruitfully tailored in personalised treatments as a therapeutic option alongside other immune-modifying agents.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Colombel J. F. Decade in review—IBD: IBD—genes, bacteria and new therapeutic strategies. Nature Reviews Gastroenterology & Hepatology. 2014;11(11):652–654. doi: 10.1038/nrgastro.2014.170. - DOI - PubMed
    1. Ek W. E., D'Amato M., Halfvarson J. The history of genetics in inflammatory bowel disease. Annals of Gastroenterology. 2014;27(4):294–303. - PMC - PubMed
    1. Vieth M., Neumann H. Current issues in IBD neoplasia. Histopathology. 2015;66(1):37–48. doi: 10.1111/his.12565. - DOI - PubMed
    1. Burger D., Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology. 2011;140(6):1827–1837. doi: 10.1053/j.gastro.2011.02.045. - DOI - PubMed
    1. Bohm S. K., Kruis W. Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis. Clinical and Experimental Gastroenterology. 2014;7:369–383. - PMC - PubMed